Sotabase

Career

· Researcher (SuperUROP), MIT Robot Locomotion Group

Publications (493)

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
New England Journal of Medicine · 2015
2,486
cited
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
New England Journal of Medicine · 2019
1,139
cited
Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile
Science Translational Medicine · 2012
1,092
cited
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.
Journal of Clinical Oncology · 2018
864
cited
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.
European Urology · 2018
484
cited
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.
Journal of Clinical Oncology · 2013
462
cited
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.
The Lancet Oncology · 2019
424
cited
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells.
Blood · 2007
400
cited
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.
Journal of Clinical Oncology · 2018
396
cited
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data
The Lancet Oncology · 2016
392
cited
Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.
Journal of Clinical Oncology · 2017
355
cited
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.
European Urology · 2020
342
cited
The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis
Cancer Epidemiology, Biomarkers and Prevention · 2012
314
cited
Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis
European Urology · 2019
263
cited
Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis.
Journal of the American Medical Association (JAMA) · 2010
256
cited
Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.
Journal of Clinical Oncology · 2014
256
cited
Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group.
Journal of Clinical Oncology · 2004
252
cited
Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.
Journal of Clinical Oncology · 2006
237
cited
Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
European Urology · 2019
227
cited
Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.
European Urology · 2018
223
cited
Sotabase